...
首页> 外文期刊>The biochemical journal >Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide
【24h】

Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide

机译:杜氏利什曼原虫拓扑异构酶II ATPase活性的表征以及对依托泊苷具有抗性的残基的鉴定

获取原文
           

摘要

pWe have cloned and expressed the 43 kDa N-terminal domain of iLeishmania donovani/i topoisomerase II. This protein has an intrinsic ATPase activity and obeys Michaelis–Menten kinetics. Cross-linking studies indicate that the N-terminal domain exists as a dimer both in the presence and absence of nucleotides. Etoposide, an effective antitumour drug, traps eukaryotic DNA topoisomerase II in a covalent complex with DNA. In the present study, we report for the first time that etoposide inhibits the ATPase activity of the recombinant N-terminal domain of iL. donovani/i topoisomerase II. We have modelled the structure of this 43 kDa protein and performed molecular docking analysis with the drug. Mutagenesis of critical amino acids in the vicinity of the ligand-binding pocket reveals less efficient inhibition of the ATPase activity of the enzyme by etoposide. Taken together, these results provide an insight for the development of newer therapeutic agents with specific selectivity./p
机译:>我们已经克隆并表达了利什曼原虫donovani 拓扑异构酶II的43 kDa N末端结构域。该蛋白具有内在的ATPase活性,并遵守Michaelis-Menten动力学。交联研究表明,无论有无核苷酸,N末端结构域均以二聚体形式存在。依托泊苷是一种有效的抗肿瘤药物,可将真核DNA拓扑异构酶II与DNA共价结合。在本研究中,我们首次报道依托泊苷抑制L重组N末端结构域的ATPase活性。 donovani 拓扑异构酶II。我们已经对该43kDa蛋白的结构进行了建模,并对该药物进行了分子对接分析。配体结合袋附近关键氨基酸的诱变表明依托泊苷对酶的ATPase活性的抑制作用较差。综上所述,这些结果为开发具有特定选择性的新型治疗剂提供了见识。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号